News
Filter
-
Separate science from politics: save the UK’s science sector
-
Promising new antibody treatment for osteoporosis and multiple sclerosis
-
Her Majesty Queen Elizabeth II
-
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
-
Seven questions about LifeArc’s 2030 ambitions
-
LifeArc helps create new MRC spin-out company
-
Driving translational research into childhood rare diseases
-
Advancing novel gene therapies into the clinic
-
Study reveals potential new way to treat colorectal cancer
-
Startup wins first Advise & Connect Innovation Award
-
Milner Therapeutics Institute and LifeArc extend strategic partnership
-
New £4.25 million grant kick starts UK-wide collaborative research effort to end motor neuron disease
